Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Joseph Levitt specializes in the treatment of adult pulmonary diseases including COPD, asthma, bronchiectasis, chronic cough, sarcoidosis, and pulmonary infections. He has practiced pulmonary medicine for more than 10 years. In addition to outpatient pulmonary medicine, Dr. Levitt is a critical care intensivist with a specific research interest in the clinical management of the Acute Respiratory Distress Syndrome (ARDS).
My research focuses on the physiolgogic and biomarker characteristics of early acute lung injury (ALI) prior to need for mechanical ventilation. While, to date no pharmacologic treatment has improved survival in ALI, following the paradigm of early goal directed therapy for severe sepsis, clinical benefit may derive from identifying patients and initiating treatment prior to the need for positive pressure ventilation (and therefore prior to meeting current study entry criteria).
Aspiration in Acute Respiratory Failure Survivors 2
The purpose of this study is to learn more about problems with swallowing that could develop
in patients who are very sick and need a machine to help them breathe.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joseph Levitt, MD, MS, .
View full details
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive
platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform
design, agents will be identified with a signal suggesting a big impact on reducing mortality
and the need for, as well as duration, of mechanical ventilation.
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient
management of patients with COVID-19. Therapeutic goals for patients hospitalized for
COVID-19 include hastening recovery and preventing progression to critical illness,
multiorgan failure, or death. Our objective is to determine whether modulating the host
tissue response improves clinical outcomes among patients with COVID-19.
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19
ACTIV-3: Therapeutics for Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
people who have been hospitalized with the infection. Participants in the study will be
treated with either a study drug plus current standard of care (SOC), or with placebo plus
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and
safety of different investigational therapeutics among adults who have COVID-19 but are not
yet sick enough to require hospitalization. The overall hypothesis is that through an
adaptive trial design, potential effective therapies (single and combination) may be
identified for this group of patients.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol
designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding
(Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the
platform, every investigational product will collect data for both Domain primary endpoints.
Individual treatments to be evaluated in the platform will be described in separate
Reevaluation Of Systemic Early Neuromuscular Blockade
This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a
patient with acute respiratory distress syndrome will improve survival. Half of the patients
will receive a neuromuscular blocker for two days and in the other half the use of
neuromuscular blockers will be discouraged.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, 6507236576.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to
assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human
Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic
Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute
Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of
hMSCs in patients with ARDS.
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled
corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory
failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed
by esophageal pressure measurement will test the primary hypothesis that using a strategy of
maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus
pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient
Statins for Acutely Injured Lungs From Sepsis
Objective: assess the efficacy and safety of oral rosuvastatin in patients with
sepsis-induced Acute Lung Injury (ALI).
Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent
pulmonary injury when administered early in hospital course to the patients at risk for
developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for
budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD),
but the use of these two drugs is experimental for ARDS.
LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of
developing acute lung injury during the first 7 days after presentation to the hospital.